New infusion aims to keep severe heart failure patients out of hospital
NCT ID NCT00610051
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tests a continuous 6-month infusion of alprostadil (ALP-1) in 600 adults with advanced heart failure and reduced pumping ability. The goal is to see if it delays death, need for a heart transplant, or worsening heart failure compared to a placebo. Participants must have severe symptoms (NYHA class IIIb or IV) and specific lab markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HFREF - HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical university Vienna
Vienna, Austria
Conditions
Explore the condition pages connected to this study.